Quick answer
Why would a laboratory choose CJC-1295 without DAC for a GH-axis experiment? Because the question is about timing. Endogenous GHRH acts in pulses against a background of somatostatin, and GH responses to GRF in rats vary with the phase of the ultradian rhythm. A stabilized analog without an albumin-binding linker gives a defined, short stimulus that can be placed at a chosen phase, then compared with a longer-persistence form. This article sets out the physiology behind pulse experiments, a design framework, the readouts and the controls, with sources. It gives no animal or human amounts. V8 lists the no-DAC reagent in 5 mg and 10 mg vials. For laboratory research use only.
The case for a short-acting GHRH analog is not that it is weaker than a long-acting one. It is that some questions can only be asked with a stimulus that starts and stops. The GH axis is rhythmic, and the time of an intervention relative to that rhythm can matter as much as its size. CJC-1295 without DAC, also written modified GRF(1-29), is a convenient tool for that kind of question because it combines the receptor-binding chain of GHRH(1-29) with protective substitutions and no albumin-reactive linker. This article is about how to design pulse experiments with such a tool and how to read the results. It is a research-design guide only; not for human or animal consumption.
The physiology that makes timing matter
GH secretion is pulsatile, and the pulses emerge from the interaction of GHRH and somatostatin. Giustina and Veldhuis (1998) describe the GHRH/somatostatin–GH–IGF-I system as a multivalent feedback network that is exquisitely sensitive to neuroregulators, environmental stressors and genetic restraints, with feedback and feedforward mechanisms operating across the intact axis. A direct experimental demonstration comes from rats. Tannenbaum and Ling (1984) gave GRF peptides at the peak and at the trough of the GH rhythm and found larger GH responses at the peak. When somatostatin was immunoneutralized, the difference disappeared, and marked GH release occurred even at the trough, so the weak trough response was attributed to antagonism by endogenous circulating somatostatin. Two practical messages follow. The response to a given stimulus is not a constant of the compound but depends on the state of the system. And a stimulus that persists across phases, as a long-acting analog does, is not equivalent to a series of pulses.
What the no-DAC form contributes
The native hormone is vulnerable at its N-terminus: Frohman and colleagues (1986) showed that plasma dipeptidylaminopeptidase converts GHRH(1-44)-amide to GHRH(3-44)-amide, which has less than one-thousandth of the biological activity, with an intact-peptide half-life of 17 minutes in plasma in vitro and 6.8 minutes after intravenous administration in normal subjects. The no-DAC analog addresses this with a D-Ala2 substitution and three other residue changes (four in all), described in the CJC-1295 (No DAC) research guide. It does not carry the linker that binds albumin, so, per that guide, its GHRH-receptor signal is brief and pulse-like. That places it between the native fragment, which is cleared very fast, and the albumin conjugate, which was detected in rat plasma beyond 72 hours (Jetté and colleagues, 2005).
| Property | Native GHRH fragment | CJC-1295 without DAC | CJC-1295 with DAC |
|---|---|---|---|
| Protease resistance | Low; N-terminal cleavage | Improved by substitutions | Improved by substitutions |
| Albumin binding | None | None | Covalent, through a maleimide |
| Exposure profile in animal models | Minutes | Brief, pulse-like (V8 guide) | Days (rat plasma detection beyond 72 h) |
| Suited to | Fast, transient stimulation, limited by cleavage | Defined pulses at a chosen phase | Sustained receptor exposure |
A design framework for pulse experiments
- Define the phase. Decide whether the stimulus is placed at a known peak or trough of the GH rhythm, and how that phase is established (for example by serial sampling in a pilot animal group). Without a defined phase the experiment tests an unknown mixture of states (Tannenbaum and Ling, 1984).
- Decide what the comparison is. Peak versus trough, with and without a somatostatin-pathway manipulation (where approved), or short-acting versus long-acting form. Each answers a different question.
- Control the environment. Light cycle, feeding time, handling stress and housing all influence GH secretion, so they are held constant and reported.
- Sample densely around the stimulus. A GH pulse is a short event, and sparse sampling misses its peak and shape. The 1984 rat study used six-hour profiles to capture it.
- Choose the readouts. GH concentration, pulse amplitude, area under the curve, and downstream IGF-I where the timescale allows.
- Include a vehicle group handled identically. Handling and administration stress themselves change GH.
- Report the test article. Lot, certificate, solvent, concentration calculation and solution age.
Readouts and what each tells you
| Readout | Information | Limit |
|---|---|---|
| Plasma GH time course | Onset, amplitude and decay of a response | Depends on sampling interval and assay sensitivity |
| GH area under the curve | Integrated secretion over a window (used to compare a conjugate with its parent fragment in rats) | Hides pulse shape |
| Pituitary RNA and GH mRNA | Longer-term biosynthetic response and cell proliferation signals (reported in the knockout mouse study) | Not informative on a pulse timescale |
| Somatostatin-dependence test | How much of the response is limited by inhibitory tone | Requires an approved manipulation and appropriate controls |
| In vitro cAMP kinetics | Receptor signaling time course in pituitary cells or receptor-expressing lines | Lacks the hypothalamic and feedback context |
Why interval and persistence are not interchangeable
An experimenter might hope to mimic a long-acting analog by giving a short-acting one more often. The published knockout mouse work illustrates why that is not straightforward. The authors noted that even twice-daily administrations of a GHRH analog had been unable to normalize growth in GHRH-knockout mice, and that once-daily administration of CJC-1295 did normalize it, with less frequent intervals less effective (Alba and colleagues, 2006). The comparison is between different molecules and schedules, so it does not isolate a single variable, but it shows that the relationship between interval, persistence and effect is not a simple matter of how many times a day a stimulus is delivered. A direct test would hold the backbone constant and vary the linker, which is the logic of the DAC versus no-DAC comparison.
Receptor-level considerations
The GHRH receptor is a seven-transmembrane G-protein-linked receptor found predominantly in the pituitary, and it is essential for somatotroph proliferation and for the synthesis and secretion of GH; evidence from the ovine receptor suggests that its C-terminus may mediate down-regulation by internalization and phosphorylation (Gaylinn, 1999). For pulse work the implication is that the interval between stimuli matters, because the receptor may need time to recover after a stimulus. An experiment with two pulses close together tests a different state from one with pulses far apart, and the spacing is part of the design. The transgenic study in which sustained GRF expression raised GH and accelerated growth in mice shows what continuous exposure achieves in a genetic model (Hammer and colleagues, 1985), which is a useful contrast to a pulsed stimulus but not a substitute for one.
Reagent handling points specific to this experiment
Pulse experiments depend on a reproducible stimulus, and a stimulus is only reproducible when the stock is. Calculate the stock from the vial mass and solvent volume (c = m ÷ V; molar c = m ÷ M ÷ V with M ≈ 3,367.9 g/mol), record the calculation, and use the same preparation procedure each time; the reconstitution calculator and its guide cover the arithmetic. Keep the age and storage history of the solution with the data. The product page states 5 mg and 10 mg lyophilized vials, ≥98% HPLC purity, a molecular formula of C152H252N44O42 and storage at 2–8 °C, −20 °C for long term, protected from heat, moisture and light. Background on stability is in how long reconstituted peptides last, and on lot documentation in how to read a COA and the COA library.
Interpreting a null or small response
A weak GH response to a pulse does not necessarily mean the reagent failed. At a trough phase, endogenous somatostatin can suppress the response, as the rat experiments showed (Tannenbaum and Ling, 1984). Before concluding that a preparation is inactive, check four things in order: the identity and concentration of the stock, the phase at which it was applied, the state of the animals (stress, fasting, light cycle) and the sensitivity of the GH assay. Only when those are controlled does a small response say something about the molecule. A positive control, such as the unmodified fragment given at a matched phase, helps separate a reagent problem from a system state.
The same reasoning applies in cell assays. A pituitary cell preparation that has been in culture for a long time or at high density may respond differently from a fresh one, and receptor expression changes with passage. Report cell source, passage and receptor expression where known, and run a reference agonist on every plate so that a drift in the system is visible.
Limits and cautions
The studies cited are rodent and in vitro work, and they come from different eras, laboratories and assay systems. Results from the rat rhythm experiments used GRF peptides given intravenously and a specific immunoneutralization approach, so they do not by themselves describe how the modified analog behaves; they describe the system into which a stimulus is delivered. Nothing in this article describes use outside the laboratory or recommends an amount or schedule. Related reading: sermorelin for the unmodified fragment, CJC-1295 vs sermorelin, CJC-1295 vs ipamorelin for the secretagogue-receptor alternative, and the catalog.
For laboratory research use only.
Frequently asked questions
Why does timing matter for a GHRH analog?
In rats, GH responses to GRF were larger at the peak than at the trough of the GH rhythm, and neutralizing somatostatin removed the difference.
What does the no-DAC form lack compared with the DAC form?
The maleimide linker that binds albumin. The receptor-binding chain and protective substitutions are the same.
How long does the no-DAC form persist?
The V8 research guide describes its signal as brief and pulse-like, in contrast to the albumin conjugate, which was detected in rat plasma beyond 72 hours.
Can frequent short-acting stimulation mimic a long-acting analog?
Not simply. Published knockout mouse work noted that twice-daily administrations of a GHRH analog did not normalize growth while once-daily CJC-1295 did, but those are different molecules and schedules.
What readouts suit a pulse experiment?
Dense plasma GH time courses, pulse amplitude and area under the curve. Pituitary RNA and mRNA suit longer timescales.
What controls are essential?
A vehicle group handled identically, constant light and feeding conditions, and a defined phase for the stimulus.
Why does receptor biology limit pulse spacing?
The GHRH receptor may down-regulate through internalization and phosphorylation, so recovery time between stimuli is a variable.
Which stock formulas are needed?
Mass concentration is m ÷ V and molar concentration is m ÷ (M × V), with M about 3,367.9 g/mol for this peptide.
What storage does the product page state?
2–8 °C, −20 °C for long term, protected from heat, moisture and light.
Does this article recommend an amount or schedule?
No. It describes experimental design for laboratory research only.
Related reading: CJC-1295 Development History: From GHRH to DAC, CJC-1295 and IGF-1: What Animal Studies Measured, CJC-1295 Mechanism of Action: GHRH Receptor Signaling.
References
- Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717-797. doi:10.1210/edrv.19.6.0353
- Tannenbaum GS, Ling N. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology. 1984;115(5):1952-1957. doi:10.1210/endo-115-5-1952
- Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest. 1986;78(4):906-913. doi:10.1172/JCI112679
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
- Gaylinn BD. Molecular and cell biology of the growth hormone-releasing hormone receptor. Growth Horm IGF Res. 1999;9(Suppl A):37-44. doi:10.1016/S1096-6374(99)80008-2
- Hammer RE, Brinster RL, Rosenfeld MG, Evans RM, Mayo KE. Expression of human growth hormone-releasing factor in transgenic mice results in increased somatic growth. Nature. 1985;315(6018):413-416. doi:10.1038/315413a0
